Serotonin 5-HT2 receptors in schizophrenia: A PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects

American Journal of Psychiatry

Volumn 156, Issue 1, 1999, Pages 72-78

  Lewis, Ralph ^b   Kapur, Shitij ^a   Jones, Corey ^b   DaSilva, Jean ^b   Brown, Gregory M ^b   Wilson, Alan A ^b   Houle, Sylvain ^b   Zipursky, Robert B ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN 2 RECEPTOR; SETOPERONE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORINE; PYRIMIDINONE DERIVATIVE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEGATIVE SYNDROME; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR DENSITY; SCHIZOPHRENIA; BRAIN CORTEX; BRAIN LEVEL; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; SCINTISCANNING;

ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CEREBRAL CORTEX; CONTRAST MEDIA; FLUORINE RADIOISOTOPES; HUMANS; PREFRONTAL CORTEX; PYRIMIDINONES; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032589898     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.1.72     Document Type: Article

References (56)

1. Breier A: Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14:187-202
2. Hattunen M: The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995; 15:4S-10S
3. Iqbal N. van Praag HM: The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995; 5:11-23
4. Bleich A, Brown S-L, van Praag HM: A serotonergic theory of schizophrenia, in The Role of Serotonin in Psychiatric Disorders. Edited by Brown S-L, van Praag HM. New York, Brunner/Mazel, 1991, pp 183-214
5. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717-719
6. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
7. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476
8. Ohuoha DC, Hyde TM, Kleinman JE: The role of serotonin in schizophrenia: an overview of the nomenclature. Psychopharmacology (Berl) 1993; 112:S5-S15
9. Meltzer HY: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15:2S-3S
10. Carpenter WT Jr: Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995; 15:30S-35S
11. Arora RC, Meltzer HY: Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res 1993; 47: 111-119
12. Pandey SC, Sharma RP, Janicak PG, Marks RC, Davis JM, Pandey GN: Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment. Psychiatry Res 1993; 48:57-68
13. Schotte A, Maloteaux JM, Laduron PM: Characterization and regional distribution of serotonin S2 receptors in human brain. Brain Res 1983; 276:231-235
14. Luabeya MK, Maloteaux JM, Laduron PM: Regional and cortical laminar distributions of serotonin S2, benzodiazepine, muscarinic, and dopamine D2 receptors in human brain. J Neurochem 1984; 43:1068-1071
15. Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain, IV: autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21:123-139
16. Radja F, LaPorte A-M, Daval GV, Verg D, Gozlan H, Hamon M: Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochem Int 1991; 18:1-15
17. Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36:927-934
18. Whitaker PM, Crow TJ, Ferrier IN: Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981; 38: 278-280
19. Reynolds GP, Rossor MN, Iversen LL: Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl 1983; 18:273-277
20. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C: Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986; 21:1407-1414
21. Arora RC, Meltzer HY: Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 1991; 85:19-29
22. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE: Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 1993; 50:810-818
23. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE: Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8:315-336
24. Dean B, Hayes W, Opeskin K, Naylor L, Pavey G, Hill C, Keks N, Copolov DL: Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Brain Res Behav Brain Res 1996; 73:169-175
25. Dean B, Hayes W: Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 1996; 21:133-139
26. Burnet PW, Eastwood SL, Harrison PJ: 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15:442-455
27. 18F]Setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol 1988; 147:73-82
28. 18F]setoperone. J Labelled Compounds and Radiopharmaceuticals 1988; 25:403-414
29. 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors. Int J Radiation Applications and Instrumentation, part B 1988; 15:463-468
30. 18F-labeled setoperone. J Neurochem 1990; 54:1744-1754
31. Seeman P: Receptor Tables: Drug Dissociation Constants for Neuroreceptors and Transporters, vol 2. Toronto, SZ Research, 1993
32. Blin J, Crouzel C: Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography. J Neurochem 1992; 58:2303-2310
33. 18F]-setoperone PET imaging. Nucl Med Commun 1997; 18:395-399
34. 18F]setoperone. Brain 1993; 116:497-510
35. 2 receptors: implications for the treatment of schizophrenia. Am J Psychiatry 1997; 154:1525-1529
36. Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JR, Guillaume M, Cantineau R, Comar D, Franck G: Serotonin 5HT(2) receptor imaging in the human brain using positron emission tomography and a new radioligand, [F-18]altanserin: results in young normal controls. J Cereb Blood Flow Metab 1995; 15:787-797
37. Crouzel C, Guillaume M, Barre L, Lemaire C, Pike VW: Ligands and tracers for PET studies of the 5-HT system - current status. Int J Radiation Applications and Instrumentation, part B 1992; 19:857-870
38. 11C]-methyl)-2-Br-LSD. Synapse 1987; 1:393-398
39. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC. American Psychiatric Press, 1995
40. Opler LA, Kay SR, Lindenmayer JP, Fiszbein A: Structured Clinical Interview for the Positive and Negative Syndrome Scale. Toronto, Multi-Health Systems, 1992
41. Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview for DSM-III-R - Non-Patient Edition (SCID-NP, Version 1.0). Washington, DC, American Psychiatric Press, 1990
42. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System. Stuttgart, Germany, Georg Thieme, 1988
43. Petit-Taboue MC, Landeau B, Osmont A, Tillet I, Barre L, Baron JC: Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. J Nucl Wed 1996; 37:95-104
44. Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH: Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
45. Iyo M, Yamasaki T: The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:415-421
46. Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, MacGregor RR, Hitzemann RJ, Gur RC, Wolf AP: Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 1995; 56:PL249-PL253
47. Iqbal N, Asnis GM, Wetzler S, Kahn RS, Kay SR, van Praag HM: The MCPP challenge test in schizophrenia: hormonal and behavioral responses. Biol Psychiatry 1991; 30:770-778
48. Kahn RS, Davidson M: Serotonin receptor responsivity in schizophrenia. Int Clin Psychopharmacol 1993; 8:47-51
49. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS: m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 1993; 50:624-635
50. Abel KM, O'Keane V, Murray RM: Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br J Psychiatry 1996; 168:57-60
51. Abel KM, O'Keane V, Murray RM, Cleare AJ: Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 1997; 22:539-548
52. Lindenmayer JR, Adityanjee, Vital-Herne M, Bark N, Grochowski S, Moynihan N: Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients. Biol Psychiatry 1997; 42:6-12
53. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL: Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry 1993; 150:1337-1342
54. Curtis VA, Wright P, Reveley A, Kerwin R, Lucey JV: Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiatry 1995; 166:642-646
55. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
56. Andreasen NC, Carson R, Diksic M, Evans A, Farde L, Gjedde A, Hakim A, Lal S, Nair N, Sedvall G, Tune L, Wong DF: Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988; 14: 471-484